Is sentinel node susceptibility to metastases related to nodal immune modulation?

Cancer Journal (United States)

Volumn 21, Issue 1, 2015, Pages 39-46

  Cochran, Alistair J ^a,b   Huang, Rong Rong ^a   Su, Albert ^a   Itakura, Eijun ^a   Wen, Duan Ren ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

immune modulatory cytokines; primary melanomas; Sentinel lymph nodes (SLNs); tumor cells from primary melanomas

Indexed keywords

ANTIGEN PRESENTING CELL; BREAST CANCER; CELL MIGRATION; DENDRITIC CELL; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LYMPH FLOW; MELANOMA; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; T LYMPHOCYTE ACTIVATION; VASCULARIZATION; LYMPH NODE; LYMPH NODE METASTASIS; NEOPLASM; PATHOLOGY; PROCEDURES; SENTINEL LYMPH NODE BIOPSY;

CYTOKINE;

CYTOKINES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASMS; SENTINEL LYMPH NODE BIOPSY;

EID: 84922311409     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000094     Document Type: Review

References (113)

1. Gaynor R, Herschman HR, Irie R, et al. S100 protein: a marker for human malignant melanomas? Lancet. 1981;1:869-871.
2. Cochran AJ, Wen DR, Herschman HR, et al. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer. 1982;30:295-297.
3. CochranAJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6:659-670.
4. Fischer B, Fischer ER. Studies concerning the regional lymph node: II. Maintenance of immunity. Cancer. 1972;29:1496-1501.
5. Cochran AJ, Wen DR, Farzad Z, et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res. 1989;9:859-864.
6. Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
7. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphaticmapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000;89:236-241.
8. Cochran AJ, Morton DL, Stern S, et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol. 2001;14:604-608.
9. Lana AM, Wen DR, Cochran AJ. The morphology, immunophenotype and distribution of paracortical dendritic leucocytes in lymph nodes regional to cutaneous melanoma. Melanoma Res. 2001;11:401-410.
10. Vuylsteke RJ, Molenkamp BG, Gietema HA, et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 2004;64:8456-8460.
11. Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res. 2005;11:107-112.
12. Tsakraklides E, Tsakraklides V, Ashikari H, et al. In vitro studies of axillary lymph node cells in patients with breast cancer. J Natl Cancer Inst. 1975;54:549-556.
13. Reiss CK, Volenec FJ, HumphreyM, et al. The role of the regional lymph node in breast cancer: a comparison between nodal and systemic reactivity. J Surg Oncol. 1983;22:249-253.
14. Kokoschka E, Uchida A, Yanagawa E, et al. Spontaneous and inducible natural cytotoxicity in lymph nodes draining primary melanoma. J InvestDermatol. 1983;80:368.
15. Cochran AJ, Pihl E,Wen DR, et al. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst. 1987;78:399-405.
16. Hoon DS, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res. 1987;47:1740-1744.
17. Wen DR, Hoon DS, Chang C, et al. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother. 1989;30:277-282.
18. Farzad Z, Cochran AJ,McBride WH, et al. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res. 1990;50:3585-3588.
19. Morton BA, RameyWG, Paderon H, et al. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res. 1986;46:2121-2126.
20. Farzad Z, McBride WH, Ogbechi H, et al. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma Res. 1997;7 (suppl 2):S59-S65.
21. Hoon DS, Bowker RJ, Cochran AJ. Suppressor cell activity in melanomadraining lymph nodes. Cancer Res. 1987;47:1529-1533.
22. Cochran AJ,Wen DR,Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol. 1988;12:612-618.
23. Wong J, Cagle L, Morton D. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637-641.
24. Morton D, Cochran A, Thompson J, et al. Sentinel node biopsy for earlystage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg. 2005;242:302-311.
25. Cochran AJ, Roberts A,WenDR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumors. Pathology. 2004;36:478-484.
26. Morton D, Mozzillo N, Thompson J, et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol. 2006;13:5s.
27. Gershenwald JE, ColomeMI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.
28. GaddMA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381-387.
29. Jansen L, Nieweg OE, Peterse JL, et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000;87:484-489.
30. Clary BM, Brady MS, Lewis JJ, et al. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 2001;233:250-258.
31. Zogakis TG, Essner R,Wang HJ, et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg. 2005;140:865-871; discussion 871-862.
32. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinelnode biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.
33. Cochran AJ, Roberts AA, Saida T. The place of lymphatic mapping and sentinel node biopsy in oncology. Int J Clin Oncol. 2003;8:139-150.
34. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumorpositive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-3684.
35. Huang RR. Sentinel lymph nodes are immunosuppressed whether or not they contain metastatic melanoma. Mod Pathol. 2005;17(suppl 1):2005.
36. Gimeno MJ, Pascual G, Garcia-Honduvilla N, et al. Modulatory role of IL10 in endothelial cell damage and platelet adhesion. Histol Histopathol. 2003;18:695-702.
37. Botella-Estrada R, Dasi F, RamosD, et al. Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res. 2005;15:99-106.
38. Wang S, Fan P, Wu ZY. Preliminary study on lymphocyte subsets of sentinel lymph nodes in breast cancer patients. Zhonghua Zhong Liu Za Zhi. 2004;26:220-222.
39. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201:1089-1099.
40. Haigh PI, Lucci A, Turner RR, et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer. 2001;92:535-541.
41. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. 2003;238:538-549; discussion 549-550.
42. Huang RR. MHC-Class II molecules expression by dendritic cells correlates with activated OPD4+ T cell in sentinel and non-sentinel nodes from melanoma patients. Mod Pathol. 2004;17(suppl 1):382.
43. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
44. Laguens G, Coronato S, Laguens R, et al. Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patientswithout malignancies. Immunol Lett. 2002;84:159-162.
45. Huang RR, Wen DR, Guo J, et al. Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast J. 2000;6:225-232.
46. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneousmelanomas. J Pathol. 2003;200:255-268.
47. Sakakura K, Chikamatsu K, Sakurai T, et al. Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer. Oral Oncol. 2005;41:89-96.
48. Ishigami S, Natsugoe S, Uenosono Y, et al. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. J Gastrointest Surg. 2003;7:735-739.
49. Straten P, Dahl C, Schrama D, et al. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol Immunother. 2006;55:495-502.
50. Ross R, RossXL, Schwing J, et al. The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells. J Immunol. 1998;160:3776-3782.
51. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 2004;64:2192-2198.
52. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precedemelanomametastasis. Am J Pathol. 2007;170:774-786.
53. Negin B, Panka D, Wang W, et al. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res. 2008;14:654-659.
54. Itakura E,Huang RR,WenDR, et al. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol. 2011;24:801-809.
55. Chevolet I, Speeckaert R, Haspeslagh M, et al. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol. 2014;171:987-995.
56. Mansfield AS, Holtan SG, Grotz TE, et al. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol. 2011;24:487-494.
57. Ma MW, Medicherla RC, Qian M, et al. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol. 2012;25:1000-1010.
58. Vallacchi V, Vergani E, Camisaschi C, et al. Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res. 2014;74:130-140.
59. Vuylsteke RJ, Molenkamp BG, van Leeuwen PA, et al. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res. 2006;12:2826-2833.
60. Thomas SN, Vokali E, Lund AW, et al. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 2014;35:814-824.
61. Inaba K, Pack M, InabaM, et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med. 1997;186:665-672.
62. Poindexter NJ, Sahin A, Hunt KK, et al. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 2004;6:R408-R415.
63. Schüle JM, Bergkvist L, Hakansson L, et al. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J TranslMed. 2004;2:45.
64. Peguet-Navarro J, Sportouch M, Popa I, et al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol. 2003;170:3488-3494.
65. Essner R, Kojima M. Surgical and molecular approaches to the sentinel lymph nodes. Ann Surg Oncol. 2001;8:31S-34S.
66. PaluckaKA, Taquet N, Sanchez-Chapuis F, et al. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol. 1998;160:4587-4595.
67. Geissmann F, Dieu-Nosjean MC, Dezutter C, et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med. 2002;196:417-430.
68. Itakura E. Is sentinel node susceptibility to metastases influenced by tumour-derived cytokines? Mod Pathol. 2004;19(suppl 1):385.
69. Leong SP, Peng M, Zhou YM, et al. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol. 2002;9:82-87.
70. Essner R, Kojima M. Dendritic cell function in sentinel nodes. Oncology (Williston Park). 2002;16:27-31.
71. Yue FY, Dummer R,Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997;71:630-637.
72. Steinbrink K, Jonuleit H, Muller G, et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood. 1999;93:1634-1642.
73. Steinbrink K, Graulich E, Kubsch S, et al. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood. 2002;99:2468-2476.
74. Takayama T, Tahara H, Thomson AW. Differential effects ofmyeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth. Transplantation. 2001;71:1334-1340.
75. Seo N, Hayakawa S, Takigawa M, et al. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology. 2001;103: 449-457.
76. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297:1867-1870.
77. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459-468.
78. MunnDH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193.
79. Widner B,Weiss G, Fuchs D. Tryptophan degradation to control T-cell responsiveness. Immunol Today. 2000;21:250.
80. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000;52:145-176.
81. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373-386.
82. Forster R, SchubelA, BreitfeldD, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999;99:23-33.
83. NakanoH, Tamura T, Yoshimoto T, et al. Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur J Immunol. 1997; 27:215-221.
84. Willimann K, Legler DF, Loetscher M, et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol. 1998;28: 2025-2034.
85. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
86. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol. 2002;2:957-964.
87. Yoshida R, Nagira M, Kitaura M, et al. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem. 1998;273:7118-7122.
88. Yanagihara S, Komura E, Nagafune J, et al. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol. 1998;161:3096-3102.
89. GunnMD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999;189:451-460.
90. Gunn MD, Tangemann K, Tam C, et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. 1998;95:258-263.
91. Takeuchi H, Fujimoto A, Tanaka M, et al. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res. 2004;10:2351-2358.
92. Hoon DS, Irie RF, Cochran AJ. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cell Immunol. 1988;111:410-419.
93. Hoon DS, Jung T, Naungayan J, et al. Modulation of human macrophage functions by gangliosides. Immunol Lett. 1989;20:269-275.
94. Cochran AJ. Effect of indomethacin on the immunocompetence of human tumour-draining lymph nodes. Fed Proc. 1985;44:965A.
95. Gupta R, Morton D. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line. J Natl Cancer Inst. 1984;72:83.
96. Hendrix MJ, Seftor EA, Kirschmann DA, et al. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci. 2003;995:151-161.
97. Littlepage LE, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell. 2005;7:499-500.
98. Vaquero J, Martinez R. Intratumoral immunotherapy with interferonalpha and interleukin-2 in glioblastoma. Neuroreport. 1992;3:981-983.
99. Ridolfi L, Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology. 2002; 49:335-339.
100. Vogelzang NJ, Lestingi TM, Sudakoff G, et al. Phase I study of immunotherapy ofmetastatic renal cell carcinoma by direct gene transfer intometastatic lesions. Hum Gene Ther. 1994;5:1357-1370.
101. Gupta RK, McElrath-Garza A, Morton DL. Role of melanoma-associated antigens. In: Hearing VJ, Leong SP, eds. From Melanocytes toMelanoma. Totowa, NJ: Humana; 2006:619-631.
102. MortonD, Eilber F, Holmes E, et al. BCGimmunotherapy of malignantmelanoma: summary of a seven-year experience. Ann Surg. 1974;180:635-643.
103. Rosenberg S, Rapp H. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am. 1976;60:419-430.
104. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
105. Leong S, Enders-Zohr P, Zhou Y, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother. 1999;22:166-174.
106. DranoffG.GM-CSF-based cancer vaccines. Immunol Rev. 2002;188:147-154.
107. Sun X, Hodge LM, Jones HP, et al. Co-expression of granulocytemacrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNAvaccination. Vaccine. 2002;20:1466-1474.
108. Kass E, Panicali DL, Mazzara G, et al. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. 2001;61:206-214.
109. Nakamura M, Iwahashi M, Nakamori M, et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res. 2002;8:2742-2749.
110. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 1996;6:247-255.
111. Pinedo HM, Buter J, Luykx-de Bakker SA, et al. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GMCSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer. 2003;39:1061-1067.
112. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, et al. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol. 2005;167:1301-1307.
113. Vaquerano JE, Cadbury P, Treseler P, et al. Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocytemacrophage colony-stimulating factor. Arch Dermatol. 1999;135:1276-1277.